HER2-low, defined as an immunohistochemistry (IHC) score of 1+ or 2+ with in situ hybridization (ISH) negativity, was reported in up to 71% in HR+ breast cancers and 53% in triple-negative breast cancers (TNBCs) [9, 10]. Here, ERBB2 is linked to breast cancer.